Allingham- Glaucoma, 7ed

424

Sección III • Manejo del glaucoma

86. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide- timolol combination versus the concomitant drugs. Am J Ophthalmol . 2000;130(6):832-833. 87. Craven ER, Walters TR, Williams R, et al., Combigan Study Group. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hyperten- sion. J Ocul Pharmacol Ther . 2005;21(4):337-348. 88. Realini T, Nguyen QH, Katz G, DuBiner H. Fixed-combination brinzol- amide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or bri- monidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies. Eye . 2013;27(7):841-847.

89. Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology . 2000;107(6):1171-1177. 90. Moroi SE, Raoof DA, Reed DM, Zollner S, Qin Z, Richards JE. Progress toward personalized medicine for glaucoma. Expert Rev Ophthalmol . 2009;4(2):145-161.

Sample